Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study

Elena Pezzolo; Alessio Gambardella; Mario Guanti; Tommaso Bianchelli; Alberto Bertoldi; Alfredo Giacchetti; Massino Donini; Giuseppe Argenziano; Luigi Naldi

doi:10.1016/j.jaad.2023.04.056

Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study

J Am Acad Dermatol. 2023 Aug;89(2):430-432. doi: 10.1016/j.jaad.2023.04.056. Epub 2023 May 5.

Authors

Elena Pezzolo¹, Alessio Gambardella², Mario Guanti³, Tommaso Bianchelli⁴, Alberto Bertoldi⁵, Alfredo Giacchetti⁴, Massino Donini⁵, Giuseppe Argenziano², Luigi Naldi⁶

Affiliations

¹ Department of Dermatology, San Bortolo Hospital, Vicenza, Italy; A Study Centre of the Italian Group for the Epidemiologic Research in Dermatology (GISED), Bergamo, Italy. Electronic address: elena.pezzolo@aulss8.veneto.it.
² Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
³ Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.
⁴ Dermatology Unit, Istituto Nazionale di Riposo e Cura per Anziani, INRCA-IRCCS Hospital, Ancona, Italy.
⁵ Department of Dermatology, Ospedale civile Santi Giovanni e Paolo Castello, Venice, Italy.
⁶ Department of Dermatology, San Bortolo Hospital, Vicenza, Italy; A Study Centre of the Italian Group for the Epidemiologic Research in Dermatology (GISED), Bergamo, Italy.

PMID: 37150301
DOI: 10.1016/j.jaad.2023.04.056

No abstract available

Keywords: atopic dermatitis; dermatology quality of life index; eczema area and severity index; efficacy; itch numeric rating scale; prurigo nodularis; real-world; safety; sleeplessness-numeric rating scale; tralokinumab.

Publication types

Multicenter Study

MeSH terms

Dermatitis, Atopic* / drug therapy
Humans
Neurodermatitis*
Phenotype
Prospective Studies
Prurigo* / drug therapy
Pruritus
Severity of Illness Index

Substances

tralokinumab